XW003
Evidence Grade E — Very limited evidence. 9 published studies. 4 registered clinical trials.
Ecnoglutide is a once-weekly GLP-1 treatment developed by Sciwind Biosciences in China, with a unique pharmacological feature: an extreme signalling bias that keeps the GLP-1 receptor available at the cell surface for longer, theoretically sustaining the drug's effect. Phase III trials have shown competitive weight loss results, and a partnership with Pfizer for commercialisation provides significant commercial validation.
9 published studies: 7 human, 0 animal, 1 in-vitro, 3 reviews
Ecnoglutide is in Phase III development (not yet approved). The SLIMMER Phase III trial (664 patients, 48 weeks) showed 15.4% weight loss at the 2.4 mg dose. A separate Phase III diabetes trial showed HbA1c reduction of 2.43%.
Ecnoglutide's biased agonism profile is its key differentiator within the competitive GLP-1 agonist landscape. Whether the extreme signalling bias translates to meaningful clinical advantages in tolerability or sustained efficacy compared to existing GLP-1 agonists will be determined by ongoing comparative data.
Ecnoglutide activates the GLP-1 receptor with exceptional selectivity for the cAMP signalling pathway while minimally triggering receptor internalisation (the process that normally reduces receptor availability after drug exposure). This biased agonism theoretically maintains receptor sensitivity over time, potentially sustaining drug effect and reducing the dose escalation needed with conventional GLP-1 agonists.
Phase III results (SLIMMER trial, 664 patients) showed 15.4% weight loss at 48 weeks, competitive with semaglutide. The extreme signalling bias (over 500,000-fold preference for one pathway over another) is genuinely novel among GLP-1 drugs. A partnership with Pfizer for Chinese commercialisation provides significant validation. All Phase III data are from Chinese populations only, and no trials outside China are planned. An oral formulation remains at Phase I with limited data. The 15.4% weight loss is competitive but not class-leading in a landscape where newer multi-target drugs are achieving over 20%. Whether the biased signalling translates to meaningful tolerability or durability advantages over conventional GLP-1 drugs remains to be demonstrated.
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Liraglutide is marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for weight management (approved 2014). The LEADER trial, involving over 9,300 patients followed for nearly four years, established that liraglutide reduced the risk of major cardiovascular events by 13% — a landmark finding that helped establish GLP-1 treatments as a class with heart benefits. Saxenda is also approved for adolescents aged 12 and older. While historically significant, liraglutide has been substantially surpassed by newer agents. In a direct comparison, semaglutide achieved 15.8% weight loss compared to liraglutide's 6.4%. Liraglutide remains relevant as a lower-intensity option and as a benchmark against which newer treatments are measured. It has over a decade of real-world safety data, making it one of the best-understood medications in this class.
Setmelanotide is marketed as Imcivree (Rhythm Pharmaceuticals; approved November 2020 for POMC, PCSK1, or LEPR deficiency; June 2022 for Bardet-Biedl syndrome; December 2024 expanded to patients aged 2 years and older). Genetic testing confirming an eligible mutation is required before treatment. In patients with POMC or PCSK1 deficiency, approximately 80% achieved at least 10% weight loss in clinical trials. In Bardet-Biedl syndrome, 32.3% achieved the same threshold. The most common side effects are injection-site reactions and skin darkening (due to the melanocortin pathway's connection to pigmentation). Setmelanotide exemplifies precision medicine — it is highly effective in the specific genetic populations it targets but is not indicated for common obesity.
HGH Fragment 176-191 has no marketing authorisation. A Phase IIa trial in obesity (approximately 300 patients) failed to demonstrate statistically significant weight loss at any dose tested. The clinical development programme was discontinued. The disconnect between animal data (which showed significant fat reduction in obese mice) and the failed human trial is the defining feature of this compound's development history. Products available through unregulated channels lack pharmaceutical quality assurance. The failed Phase II trial represents the highest level of clinical evidence available.
